33 Proteomics, Genomics & Microarrys
New Media and Feeds Maximise Yield and Batch-to-Batch Consistency to Support Recombinant Protein Production Scale-Up
Lonza has expanded its cell culture media portfolio with the addition of the GSv9™ Media and Feeds, providing a fully integrated solution specifi cally designed to optimise recombinant protein production using Lonza’s GS Gene Expression System®. The new chemically defi ned, animal-component free media and feeds are easy to implement, highly robust and enable greater batch-to-batch consistency. As a result, biopharmaceutical manufacturers can more easily develop streamlined and scalable bioproduction processes.
Recombinant proteins derived from mammalian cell lines are a key source of biopharmaceuticals designed to treat many complex human diseases. However, in such a highly competitive market, biopharmaceutical manufacturers must ensure that they maximise protein yield and consistency whilst also expediting production times. One way to achieve this is by using specially developed, simple-to-use media and feeds that improve cellular productivity, streamline processing and eliminate sources of product variability.
With a focus on ease of implementation, Lonza is introducing the new GSv9™ Media and Feeds that deliver high performance with a simple and easy to use protocol. Furthermore, the solution has been developed using response surface optimisation and multivariate propagation of error analysis to increase the intrinsic robustness of the production process. Additionally, the overall culturing time is designed for high facility throughput.
Colin Jaques, Technical Director, Lonza Biologics: “Developing a commercially successful bioproduction process hinges on having a robust culturing platform that can reproducibly generate high-quality, stable proteins. The GSv9™ Media and Feeds have been designed with these challenges in mind, offering an easy-to-use solution for customers using our GS Gene Expression System®. Drawing on more than 35 years of mammalian expression, process development and manufacturing experience, GSv9™ Media and Feeds is a newly developed highly robust platform that maximises cell concentration and protein yields while cutting production time. As a result, we’re helping our customers to accelerate time to market for the next generation of therapeutics.”
More information online:
ilmt.co/PL/mBEB 52601pr@reply-direct.com
NGS Panel for Constitutional Cytogenetics Launched
Oxford Gene Technology (OGT), A Sysmex Group Company, has launched a transformative next-generation sequencing (NGS) panel for constitutional cytogenetics research. The CytoSure™ Constitutional NGS Panel contains the most up-to-date, hand- curated content for intellectual disability (ID) and developmental delay (DD) research. Delivering accurate and reliable detection of copy number variations (CNVs), single nucleotide variations (SNVs), insertion/deletions (indels) and loss of heterozygosity (LOH) - including in mosaic samples - the panel combines the benefi ts of NGS and microarrays in one cost-effective assay.
OGT’s CytoSure brand is renowned for excellence in constitutional cytogenetics, with its popular Constitutional v3 microarrays in wide use across major laboratories worldwide. There is a desire within constitutional genetics laboratories to transition to NGS technologies, however it has often been problematic to achieve accurate single-exon CNV and LOH detection on these platforms. OGT’s expertise combined with a long heritage in hybridisation technologies, design and software, has enabled the company to overcome this challenge, producing CNV data quality that is second to none. Data produced from the CytoSure Constitutional NGS panel is of the highest quality and shows excellent concordance with arrays. The intuitive, user-friendly software means there is no need for large bioinformatics teams to work alongside labs for data analysis.
The empirically-optimised CytoSure Constitutional NGS panel, designed in collaboration with leading cytogenetics experts and consortia, targets over 700 genes at the exon level. The panel has been rigorously tested in cytogenetics labs in order to ensure the highest possible performance and confi dence in results. Alpha and beta triallists were particularly pleased with the detection capabilities and software ease of use.
Designed to be run on the Illumina NextSeq™ or NovaSeq™, the CytoSure Constitutional NGS solution includes hybridisation capture baits, a complete library preparation kit (including hyb/wash buffer) and powerful complimentary analysis software for SNV, indel, CNV and LOH interpretation. OGT’s popular, easy-to-use Interpret software delivers confi dent, dependable data analysis and is a familiar visual platform for cytogeneticists - facilitating an easy transition to NGS.
Available at a similar cost to arrays (but yielding substantially more informative data), the CytoSure Constitutional NGS panel offers a more cost-effective solution than whole exome sequencing, reducing the costs of data storage whilst minimising detection of variants of uncertain signifi cance (VUS) which are often seen as time consuming to analyse.
For more information please visit:
ilmt.co/PL/4V5o 52313pr@reply-direct.com
New Range of SARS-CoV-2 Spike Protein Products Launched
Amsbio has launched a range of ready-to-use SARS-CoV-2 Spike protein coupled magnetic beads that combine convenience, minimum non-specifi c binding and developed operational protocols saving you time and hassle.
Developed for immunocapture, cell stimulating, biopanning and fl ow cytometry applications these new products use biotinylated SARS-CoV-2 Spike protein pre-coupled to streptavidin conjugated magnetic beads, which can capture the Anti-SARS-CoV-2 antibody or ACE2 protein from cell or serum sample. Because Streptavidin has an extraordinarily high affi nity for biotin with a dissociation constant (Kd) on the order of 10-14 mol/L, the biotinylated protein can bind to the magnetic beads irreversibly.
The complex may be removed from the solution manually using a magnetic separator. The bound SARS-CoV-2 spike proteins can then be dissociated from the magnetic beads using an elution buffer. All magnetic bead products from AMSBIO are of uniform size, narrow size distribution with large surface area and unique surface coating, which delivers industry-leading performance and highly reproducible results. Amsbio also offers a Custom Magnetic Beads service to provide you with the best possible tools for your specifi c research project.
Amsbio has also introduced new SARS-CoV2 Spike S1 protein-coated and SARS-CoV2 Spike protein RBD-Coated microplates optimised for ELISA Assay and Biopannning. These assay kits employ a standard Indirect-ELISA format which provide a rapid quantifi cation of Anti-SARS-CoV-2 antibodies or ACE-2 protein in serum by binding to Spike protein S1. Key advantages of these new plates include time saving (pre-coated and blocked), fl exible experimental design (detachable 8-well strips) and that they are proven to eliminate problems associated with denaturing of the protein component of a conjugate upon binding. These new coated plates are ideal for binding anti-SARS2-CoV-2 antibodies or ACE2 protein that typically exhibit poor binding to polystyrene.
With infections spread globally, COVID-19 was declared a pandemic outbreak by the World Health Organization on 11 March 2020. The development of vaccines, diagnostics, and therapeutics is vital for the ongoing control of the outbreak. Amsbio provide an ever-expanding collection of tools for SARS-CoV-2 and Coronavirus research, including recombinant proteins, antibodies, inhibitor screening kits, and other assay kits.
More information online:
ilmt.co/PL/Ko1g 52603pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
